The European Medicines Agency extends the shelf life of the antigens used in Strangvac to 28 months.
Stockholm, March 9, 2022 - The European Medicines Agency has today, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months. The manufacturing of Strangvac, a vaccine against the highly contagious equine disease strangles, takes place in two steps - first the antigens are produced in a process that yields sufficient antigens for several million doses, then vaccine doses are produced by mixing the antigens with adjuvant and saline. The reconstituted vaccine doses are transferred into vials that are labelled and packaged for sale.